Novel formulations of cetrorelix acetate in healthy men: Pharmacodynamic effects and noncompartmental pharmacokinetics

Journal of Clinical Pharmacology

Volumn 42, Issue 9, 2002, Pages 995-1001

  Erb, Katharina ^a,b   Junge, Klaus ^a   Pechstein, Birgit ^a   Schneider, Edith ^a   Derendorf, Hartmut ^c   Hermann, Robert ^a  

^a Viatris Inc   (Germany)

^b Clinphase   (Germany)

^c UNIVERSITY OF FLORIDA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CETRORELIX; FOLLITROPIN; GLUCONIC ACID; LUTEINIZING HORMONE; TESTOSTERONE; DRUG DERIVATIVE; GONADORELIN; HORMONE ANTAGONIST;

ADULT; AREA UNDER THE CURVE; ARTICLE; CLINICAL TRIAL; CONCENTRATION RESPONSE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DOSE TIME EFFECT RELATION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG EFFECT; DRUG FORMULATION; HORMONE ACTION; HORMONE DETERMINATION; HUMAN; HUMAN EXPERIMENT; LUTEINIZING HORMONE RELEASE; MALE; MAXIMUM PERMISSIBLE DOSE; NORMAL HUMAN; RADIOIMMUNOASSAY; RANDOMIZED CONTROLLED TRIAL; STATISTICAL SIGNIFICANCE; TESTOSTERONE RELEASE; BIOAVAILABILITY; BLOOD; ENZYME IMMUNOASSAY; HALF LIFE TIME;

ADULT; AREA UNDER CURVE; BIOLOGICAL AVAILABILITY; FOLLICLE STIMULATING HORMONE; GLUCONATES; GONADOTROPIN-RELEASING HORMONE; HALF-LIFE; HORMONE ANTAGONISTS; HUMANS; IMMUNOENZYME TECHNIQUES; LUTEINIZING HORMONE; MALE; RADIOIMMUNOASSAY; TESTOSTERONE;

EID: 0036708026     PISSN: 00912700     EISSN: None     Source Type: Journal    
DOI: 10.1177/0091270002042009006     Document Type: Article

References (25)

1. Gonadotropin-releasing hormone and its analogues
2. Pharmacodynamic and pharmacokinetic effects of single subcutaneous doses of cetrorelix acetate in healthy premenopausal women
3. Pituitary and gonadal endocrine effects and pharmacokinetics of the novel LHRH antagonist teverelix in healthy men: A first-dose-in-humans study
4. Suppression of the endogenous luteinizing hormone surge by the gonadotrophin-releasing hormone antagonist cetrorelix during ovarian stimulation
5. A single injection of a gonadotropin-releasing hormone (GnRH) antagonist (cetrorelix) postpones the luteinizing hormone (LH) surge: Further evidence for the role of GnRH during the LH surge
6. Comparison of different doses of gonadotropin-releasing hormone antagonist cetrorelix during controlled ovarian hyperstimulation
7. The use of a GnRH antagonist (cetrorelix) in a single dose protocol in IVF-embryo transfer: A dose finding study 3 versus 2 mg
8. Ganirelix
9. Hormonal therapy in the management of prostate cancer: An historical overview
10. Development of GnRH antagonists for prostate cancer: New approaches to treatment
11. Hormone therapy for patients with prostate carcinoma
12. Endocrine and adrenergic pharmacological intervention in diseases of the prostate
13. Optimal therapy for advanced prostatic carcinoma
14. Efficacy and safety of luteinizing hormone-releasing hormone antagonist cetrorelix in the treatment of symptomatic benign prostatic hyperplasia
15. A randomized double blind placebo controlled phase II study of the safety and efficacy of cetrorelix in men with BPH
16. Treatment of uterine leiomyomas with luteinizing hormone-releasing hormone antagonist cetrorelix
17. Treatment of uterine fibroids with a slow-release formulation of the gonadotrophin releasing hormone antagonist cetrorelix
18. Endometriosis and the estrogen threshold theory: Relation to surgical and medical treatment
19. Pharmacokinetic-pharmacodynamic modeling of testosterone and luteinizing hormone suppression by cetrorelix in healthy volunteers
20. Development of radioimmunoassay for a potent luteinizing hormonereleasing hormone antagonist: Evaluation of serum levels after injection of [Ac-342-naphthyl)-D-Ala1, D-Phe(pCl)2,3-(3-pyridyl)-D-Ala3, D-Cit6, D-Ala10] LHRH
21. The pituitary gland secrets in bursts: Appraising the nature of glandular secretors impulses by simultaneous multiple-parameter deconvolution of plasma hormone concentrations
22. Selection and characterization of mammalian cell lines with stable over-expression of human pituitary receptors for gonadoliberin
23. Characterization of gonadotropinreleasing hormone analogs based on a sensitive cellular luciferase reporter gene assay
24. Regulation of biologically active dimeric inhibin A and B from infancy to adulthood in the male
25. A clinician's guide to the use of gonadotropinreleasing hormone analogues in women